Table 2.
Estimated KM overall survival at 8 years for all variables.
| Variable | Matched sample (N = 5,430) |
Whole sample (N = 33,638) |
||
|---|---|---|---|---|
| % survived at 8 years | Log-rank p-value | % survived at 8 years | Log-rank p-value | |
| Treatment | 0.6483 | 0.0056 | ||
| IMRT | 77.23 | 75.50 | ||
| SBRT | 79.38 | 79.38 | ||
| Age | <0.0001 | <0.0001 | ||
| <55 | 98.60 | 87.42 | ||
| 55–59 | 79.63 | 85.85 | ||
| 60–64 | 93.47 | 84.44 | ||
| 65–69 | 81.85 | 80.26 | ||
| 70–74 | 78.35 | 76.24 | ||
| 75–90 | 59.77 | 63.73 | ||
| Race | 0.2813 | 0.0003 | ||
| Black | 83.99 | 75.96 | ||
| Other | 71.87 | 79.84 | ||
| Unknown | 100.00 | 84.05 | ||
| White | 77.60 | 75.38 | ||
| Insurance status | 0.0002 | <0.0001 | ||
| Insurance status unknown | 78.28 | 77.01 | ||
| Medicaid | 69.54 | |||
| Medicare | 74.41 | 72.21 | ||
| Not insured | 86.60 | 76.88 | ||
| Other government | 89.84 | 77.71 | ||
| Private insurance | 84.80 | 83.35 | ||
| Patient residence | 0.0145 | 0.0599 | ||
| Metropolitan | 79.45 | 76.14 | ||
| Rural | 61.00 | 69.61 | ||
| Urban | 63.89 | 73.41 | ||
| Median household income (US$) | 0.0059 | <0.0001 | ||
| <38,000 | 78.13 | 72.58 | ||
| 38,000–47,999 | 63.15 | 73.25 | ||
| 48,000–62,999 | 81.35 | 75.64 | ||
| 63,000+ | 80.88 | 78.48 | ||
| Charlson–Deyo comorbidity score | <0.0001 | <0.0001 | ||
| 0 | 79.32 | 77.22 | ||
| 1 | 73.73 | 64.39 | ||
| 2 | 33.20 | 53.74 | ||
| Facility type | 0.9955 | <0.0001 | ||
| Academic/research program | 75.94 | 77.74 | ||
| Community cancer program | 67.70 | 72.41 | ||
| Comprehensive community program | 80.36 | 74.75 | ||
| Integrated network cancer program | 75.57 | 77.35 | ||
| Year of diagnosis | 0.0210 | 0.0118 | ||
| 2004–2009 | 78.69 | 75.86 | ||
| 2010–2013 | ||||
| Tumor clinical stage | 0.0826 | <0.0001 | ||
| Other | 90.44 | 76.45 | ||
| T1 | 78.69 | 77.15 | ||
| T2 | 74.57 | 73.28 | ||
| T3 | 80.82 | 65.30 | ||
| Prostate-specific antigen | 0.0131 | <0.0001 | ||
| <10 | 78.65 | 77.69 | ||
| 10–20 | 72.72 | 69.27 | ||
| >20 | 77.61 | 70.62 | ||
| Gleason score | <0.0001 | <0.0001 | ||
| <7 | 81.35 | 80.65 | ||
| ≥7 | 71.96 | 70.85 | ||
| Hormone therapy | 0.0020 | <0.0001 | ||
| No | 78.49 | 78.19 | ||
| Yes | 73.05 | 70.97 | ||
| Dose level | 0.5403 | 0.1488 | ||
| Low | 76.93 | 75.77 | ||
| Intermediate | 77.86 | 75.15 | ||
| High | 86.18 | 77.22 | ||